Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Choosing Lean means choosing excellence, care, and expertise
Glucagon-like peptide 1 (GLP-1) agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists such as semaglutide and tirzepatide are approved by the United States Food and Drug Administration (FDA) for the management of obesity
These include: Semaglutide (Wegovy) recommended by NICE for weight management in eligible adults (NICE TA875) Liraglutide (Saxenda) recommended by NICE for weight management in selected groups (NICE TA664) Orlistat available for weight management under NICE guidance (NICE CG189) Naltrexone/bupropion (Mysimba) does not currently have a positive NICE recommendation for weight management in England and should not be assumed to be a routinely recommended option
Past pancreatitis or severe gastrointestinal disease should be discussed with your provider to find alternative solutions
This can be easily fixed with hormone balancing and possibly medications
